Clinuvel Pharmaceuticals Limited (ASX: CUV) - ETF Exposure

Current share price for CUV : $8.020 0.24 (2.91%)⁺

CLINUVEL (CUV) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photo medicine and the family of melanocortin peptides

CUV General Information ⁺

ASX Code	CUV
Website	http://www.clinuvel.com
Industry/Sector	Biotechnology
Market Cap ($M)	404
CUV Share Price	$8.020
Day High	$8.270
Day Low	$7.970
Last Close	$8.260
CUV Share Price Movement	$0.24 ( 2.91% )

Prices as at 16:40, 25 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CUV

Clinuvel Pharmaceuticals Limited (CUV) is held across 13 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when CUV moves, funds like SSO, ISO, MQAE, DAVA and DACE that hold it can move with it.

For more concentrated exposure, ETFs such as SSO (State Street SPDR S&P/ASX Small Ordinaries ETF) allocate about 0.1% to CUV , while the average exposure across all 13 ETFs that hold it is around 0% .

Top ETF holdings

State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) ~ 0.1%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0.1%
Macquarie Core Australian Equity Active ETF (MQAE) ~ 0.1%
Dimensional Australian Value Trust - Active ETF (DAVA) ~ 0%
Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 25 September 2026

Own CUV directly or through an ETF?

How does holding Clinuvel Pharmaceuticals Limited (CUV) shares directly compare to ETFs that include it?

	CUV Direct	SSO ASX	ISO ASX	MQAE ASX	DAVA ASX	DACE ASX
Holdings	1 company	218 holdings	218 holdings	219 holdings	167 holdings	485 holdings
CUV Weight	100%	0.1%	0.1%	0.1%	0%	0%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	0.5% p.a.	0.55% p.a.	0.03% p.a.	0.34% p.a.	0.28% p.a.
Approx. Yield	0.5%	9.3%	4.36%	2.61%	6.6%	3.05%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CUV's direct yield. Annual cost uses each ETF's MER.

CUV Exposure on $10,000 investment

How a $10,000 investment in Clinuvel Pharmaceuticals Limited (CUV) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Clinuvel Pharmaceuticals Limited (CUV)	Direct share	$8.020	-4.18%	-$418	$9,582
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	Equity - Australia Small/Mid Cap	$14.420	-1.37%	-$137	$9,863
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$5.010	-1.18%	-$118	$9,882
Macquarie Core Australian Equity Active ETF (MQAE)	Equity - Australia Strategy	$11.870	-0.50%	-$50	$9,950
Dimensional Australian Value Trust - Active ETF (DAVA)	Equity - Australia Strategy	$31.410	-0.82%	-$82	$9,918
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$18.740	-0.85%	-$85	$9,915

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Clinuvel Pharmaceuticals Limited (CUV) ETFs

13 ETFs hold Clinuvel Pharmaceuticals Limited (CUV).

ETF	CUV Weight	MER	Yield
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	0.1%	0.5%	9.3%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0.1%	0.55%	4.36%
Macquarie Core Australian Equity Active ETF (MQAE)	0.1%	0.03%	2.61%
Dimensional Australian Value Trust - Active ETF (DAVA)	0%	0.34%	6.6%
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	3.05%
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0%	0.16%	3.8%
Global X Australia 300 ETF (A300)	0%	0.03%	3.04%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	4.18%

View all 13 ETFs

Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
HFResult	5¢	100%	3 Sep 2026	18 Sep 2026	-	-	-
HFResult	5¢	100%	4 Sep 2025	19 Sep 2025	-	-	-
HFResult	5¢	100%	5 Sep 2024	20 Sep 2024	-	-	-

See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clinuvel Pharmaceuticals Limited (CUV) price-sensitive announcements

CUV - Commercial update on vitiligo

CLINUVEL PHARMACEUTICALS LTD provided a commercial update on vitiligo treatments, focusing

Clinuvel Pharmaceuticals Limited (CUV)
30 Jul 2026 | 8:57 AM

CUV - Update - SCENESSE in vitiligo

Clinuvel Pharmaceuticals Limited is advancing its SCENESSE® (afamelanotide) drug in combin

Clinuvel Pharmaceuticals Limited (CUV)
28 Jul 2026 | 8:56 AM

CUV - CLINUVEL strategic reorganisation to refocus on U.S. markets

CLINUVEL Pharmaceuticals Limited announced a strategic reorganisation to refocus its opera

Clinuvel Pharmaceuticals Limited (CUV)
23 Jul 2026 | 9:11 AM

CUV - SCENESSE approved for EPP in Canada

Clinuvel Pharmaceuticals Limited announced that its novel drug SCENESSE® (afamelanotide) h

Clinuvel Pharmaceuticals Limited (CUV)
13 Jul 2026 | 8:34 AM

Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	Becoming a substantial holder	24 Sep 2026 8:19AM	$8.280	$8.020	fallen by 3.14%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	CLINUVEL date of Annual General Meeting	18 Sep 2026 5:12PM	$8.370	$8.020	fallen by 4.18%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	CLINUVEL develops proprietary ZEROKIN device	8 Sep 2026 9:32AM	$8.160	$8.020	fallen by 1.72%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	Ceasing to be a substantial holder	2 Sep 2026 8:15AM	$8.240	$8.020	fallen by 2.67%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	CLINUVEL considers Nasdaq listing, ASX delisting	27 Aug 2026 12:33PM	$10.690	$8.020	fallen by 24.98%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$404	Investor Presentation	27 Aug 2026 12:28PM	$10.690	$8.020	fallen by 24.98%

CUV Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	DPS	Yield (%)	Franking (%)
2028F	C2	$63.50	2.40%	12.60	5.00	0.60%	0.0%
2027F	C2	$62.00	-7.20%	12.90	5.00	0.60%	0.0%
2026A	$33.92	$66.80	-7.00%	16.40	5.00	0.50%	100.0%

CUV Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
CSL Limited (CSL)	$85,957M	0.7309	-0.4440	0.0545	11.0969	19.9585	18.9263	2.37%	2.32%	2.40%
Clinuvel Pharmaceuticals Limited (CUV)	$417M	-0.0696	-0.0719	0.0242	12.3653	13.3226	13.0079	0.61%	0.61%	0.61%
Mesoblast Limited (MSB)	$2,844M	-0.4380	0.0000	0.0000	0.0000	0.0000	347.6190	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$2,862M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,350M	-1.3893	0.0000	-0.2777	0.0000	174.1150	241.0413	0.00%	0.00%	0.00%

CUV Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.20	12.20	1.48	0.00
Market	0.33	13.80	1.17	0.79
Sector	0.63	30.70	2.72	1.90

CUV Directors

Name	Position	Start Date
Dr Philippe J Wolgen	Chief Executive Officer, Managing Director	1 Oct 2005
Professor Jeffrey Rosenfeld	Non-Executive Chairman, Non-Executive Director	26 Nov 2019
Mrs Susan (Sue) Smith	Non-Executive Director	23 Sep 2019
Dr Karen Agersborg	Non-Executive Director	29 Jan 2018
Mr Matthew William Pringle	Non-Executive Director	6 Sep 2024
Dr Pearl E Grimes	Non-Executive Director	6 Sep 2024
Mr Guy van Dievoet	Non-Executive Director	6 Sep 2024

Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
19 Sep 2023	WOLGEN, Philippe	Buy	Direct Shares	1,850	$16.116	$29,813.860
26 Jun 2023	WOLGEN, Philippe	Buy	Direct Shares	1,532	$17.720	$27,147.330
4 Nov 2022	ROSENFELD, Jeffrey	Buy	Indirect Shares	300	$19.440	$5,832.000

See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CUV Management

Name	Position
Claire Newstead-Sinclair	Company Secretary

CUV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
3,524,439 (7%)	JPMorgan Chase and Co and its affiliates
3,354,676 (6.70%)	The Bank of New York Mellon Corporation
3,124,097 (6.20%)	Dr Philippe Jacques Wolgen
2,523,018 (5%)	The Vanguard Group,Inc
2,340,824 (4.60%)	Ender 1, LLC and SNP Ventures Group Member

CUV Calendar of Events

Date	Event
26 August 2027	Report (Annual)
26 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us